Skip to main content

Table 1 The clinical characteristic of the total subjects enrolled

From: Prognostic prediction of subjective cognitive decline in major depressive disorder based on immune biomarkers: a prospective observational study

Variables

Total(n = 50)

Age

Mean (SD)

27.31(7.21)

Gender

Male, n (%)

11(22%)

Female, n (%)

39(78%)

Education level

Mean (SD)

15.04(3.02)

Marital status

Single, n (%)

27(54%)

Married, n (%)

20(40%)

Divorced, n (%)

3(6%)

Employment status

Employed, n (%)

32(64%)

Unemployed, n (%)

18(36%)

Smoking

Yes, n (%)

12(24%)

No, n (%)

38(76%)

Drinking

Yes, n (%)

16(32%)

No, n (%)

34(68%)

Height

Mean (SD)

164.54(7.77)

Weight

Mean (SD)

56.38(11.29)

BMI

Mean (SD)

23.87(7.23)

Age of MDD onset (years)

Mean (SD)

23.88(7.23)

History of MDD episode

First episode, n (%)

25(50%)

Recurrent episode, n (%)

25(50%)

Total course, month

Mean (SD)

31.38(36.09)

Baseline HRSD17 score

Mean (SD)

23.02(4.77)

Antidepressant drugs (ES/VF)

ES, n (%)

27(54%)

VL, n (%)

23(46%)

HRSD-17 total score reduction, %

Mean (SD)

58.75(22.94)

PDQ-D score at baseline

Mean (SD)

36.94(12.80)

PDQ-D score at 8 weeks

Mean (SD)

31.44(20.96)

SDS score at baseline

Mean (SD)

14.24(7.00)

SDS score at 8 weeks

Mean (SD)

10.58(8.18)

  1. Abbreviation: MDD Major depressive disorder, BMI Body mass index, HRSD the Hamilton Depression Rating Scale-17, ES Escitalopram, VF Venlafaxine, PDQ-D the Perceived Deficits Questionnaire-depression, SDS the Sheehan Disability Scale